Asia Spotlight: BeiGene CEO John Oyler On Building A Biotech In China
Executive Summary
The CEO of one of China’s hottest start-ups sits down to talk about his strategy, the state of innovation in China and how to access funding from the Chinese government.
You may also be interested in...
As Management Talent Moves To China Startups, Will Industry See More In-Licensing Deals?
SHANGHAI - Beijing-based biotech startup BeiGene Ltd. announced its first in-licensing deal this month for two clinical-stage oncology compounds from Janssen Pharmaceutical NV, a division of Johnson & Johnson.
Merck Invests In China Oncology Start-up BeiGene
Merck & Co. affiliate MSD has invested an undisclosed amount of debt and equity financing in the Beijing-based start-up biotech BeiGene, Ltd., BeiGene announced May 2
CROs at risk from China's new inventor regulation?
China's State Intellectual Property Office (SIPO) is drafting a new regulation on "service innovation" to encourage companies and researchers in the country to raise their investment in, and the conduct of, innovation. However, the move may also have an impact on the soaring drug discovery industry in China as it will mean higher payments to inventors with knock-on effects on local drug discovery and CROs.